Paul Hastings, BIO chair
June 9, 2022 12:31 PM EDTUpdated June 10, 12:15 AM
People
R&D

#BIO22: BIO chair Paul Hast­ings: 'I think peo­ple should speak their truth'

John Carroll

Editor & Founder

Paul Hast­ings doesn’t of­fer the usu­al biotech ex­ec­u­tive clich­es. The ones en­dorsed by the me­dia con­sul­tant crowd. And some­times the Nkar­ta CEO doesn’t even wait …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Zai Lab aims to raise $200M; Kro­nos Bio to seek ‘strate­gic’ op­tions

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times